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We identify the leucine-rich repeat transmembrane
protein LRRTM2 as a key regulator of excitatory
synapse development and function. LRRTM2 local-
izes to excitatory synapses in transfected hippo-
campal neurons, and shRNA-mediated knockdown
of LRRTM2 leads to a decrease in excitatory syn-
apses without affecting inhibitory synapses. LRRTM2
interacts with PSD-95 and regulates surface expres-
sion of AMPA receptors, and lentivirus-mediated
knockdown of LRRTM2 in vivo decreases the
strength of evoked excitatory synaptic currents.
Structure-function studies indicate that LRRTM2
induces presynaptic differentiation via the extracel-
lular LRR domain. We identify Neurexin1 as a receptor
for LRRTM2 based on affinity chromatography.
LRRTM2 binds to both Neurexin 1a and Neurexin
1b, and shRNA-mediated knockdown of Neurexin1
abrogates LRRTM2-induced presynaptic differentia-
tion. These observations indicate that an LRRTM2-
Neurexin1 interaction plays a critical role in regulating
excitatory synapse development.INTRODUCTION
The function of the brain critically depends on appropriate
synaptic connectivity. Specific patterns of connections, together
with the properties of synaptic transmission at particular syn-
apses, determine how the brain processes information. Although
significant progress has been made in elucidating the pre- and
postsynaptic organization of synapses, our understanding of
the molecular mechanisms that regulate the development and
function of CNS synapses is limited.
Synaptic cell adhesion molecules are key players in organizing
synapse formation between appropriate synaptic partners.
Hetero- or homophilic adhesive interactions across a nascent
synapse allow target cell recognition and subsequent bidirec-
tional differentiation of pre- and postsynaptic elements. Previous
work has identified several synaptic cell adhesionmolecules thatcan mediate trans-synaptic interaction to induce pre- and post-
synaptic differentiation. These synaptogenic adhesion mole-
cules include the neuroligins (Ichtchenko et al., 1995; Scheiffele
et al., 2000; Song et al., 1999), synCAM (Biederer et al., 2002),
NGL-2 and NGL-3 (Kim et al., 2006), and EphB2 (Kayser et al.,
2006).
To identify novel transmembrane proteins that might regu-
late the development and function of synapses, we carried
out an in silico screen for genes that showed subregion-
specific expression in the adult hippocampus as reported
in the Allen Brain Atlas (Lein et al., 2007) and encoded proteins
with extracellular protein-protein interaction domains. Candi-
date genes were subsequently tested for putative synapto-
genic properties in heterologous cell-neuron coculture assays
(Biederer and Scheiffele, 2007; Scheiffele et al., 2000). This
approach led to the identification of leucine-rich repeat trans-
membrane (LRRTM) proteins as proteins that could induce
presynaptic differentiation. During the course of the study,
Linhoff and colleagues reported that LRRTM proteins can
induce synapse formation in hippocampal neurons (Linhoff
et al., 2009), but several major questions remained unan-
swered. Importantly, whether endogenous LRRTMs contribute
to synaptic function in vivo was not known, and the receptors
that mediate the effects of LRRTM had not been identified.
Here we provide evidence that endogenous LRRTM2 regulates
excitatory synapse development and function in vitro and
in vivo and identify Neurexins as functional receptors for
LRRTM2.
RESULTS
LRRTM2 Regulates Excitatory Synapse Formation
in Hippocampal Neurons
The LRRTM gene family consists of four genes, LRRTM1–4.
Analysis of the LRRTM gene expression pattern by in situ hybrid-
ization showed that these genes are differentially expressed
in the developing cortex and hippocampus (Figure S1). To
determine the subcellular localization of LRRTM proteins,
we transfected 293T cells with tagged constructs and ex-
amined their distribution by immunofluorescence. Myc-tagged
LRRTM2–4 and LRRTM4L all localized to the cell membrane in
transfected 293T cells (Figure S1). LRRTM1 however remainedNeuron 64, 799–806, December 24, 2009 ª2009 Elsevier Inc. 799
Figure 1. Knockdown of LRRTM2
Decreases Excitatory Synapse Density in
Hippocampal Neurons
(A) Hippocampal neurons were cotransfected with
myc-LRRTM2 and GFP at DIV 10 and immuno-
stained for postsynaptic markers and GFP at DIV
17. Top panels, myc-LRRTM2 colocalizes with
the excitatory postsynaptic marker PSD-95 in
dendritic spines (arrowheads). Bottom panels,
myc-LRRTM2 does not colocalize with the inhibi-
tory postsynaptic marker gephyrin. GFP fluores-
cence shown in blue for better visualization.
(B) 293T cells were cotransfected with mouse
myc-LRRTM2 and the empty pSUPER vector
(sh-vector) or pSUPER containing a shRNA
against mouse and rat LRRTM2 (sh-LRRTM2) for
48 hr. The LRRTM2 shRNA reduces expression
of mouse LRRTM2 by 90%, but human myc-
LRRTM2 is not affected. Samples were probed
with a b-actin antibody to verify equal loading.
(C) Knockdown of endogenous LRRTM2 in hippo-
campal neurons. Neurons were infected with
control or sh-LRRTM2 containing lentiviral vectors
(LV) at DIV 6 and analyzed at DIV 12. LRRTM2
protein levels are strongly reduced in LV-
shLRRTM2-infected neurons compared to control
infected or uninfected neurons. PSD-95 and bIII
tubulin levels in the same samples are unchanged.
(D) Hippocampal neurons were electroporated
with the sh-vector (sh-vec), sh-LRRTM2, and
sh-LRRTM2 with human myc-LRRTM2 (sh-
LRRTM2 + hLRRTM2) and immunostained at DIV
14 for GFP, PSD-95, and VGlut1. (E) Quantification
of the density of VGlut1/PSD-95-positive puncta
per length of dendrite normalized to sh-vec control
neurons. (***p < 0.001). (F) LRRTM2 knockdown
does not affect inhibitory synapse density identi-
fied by VGAT/gephyrin colocalization. Scale bar
in (A) and (D), 10 mm. Error bars represent SEM.
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membrane domain (Laure´n et al., 2003), suggesting that
LRRTM1 may require additional proteins for proper membrane
targeting.
In a heterologous synapse induction assay, in which LRRTM
proteins expressed in 293T cells were cocultured with hippo-
campal neurons, we found that LRRTM2 was more effective
than the other LRRTM genes in inducing presynaptic differentia-
tion (Figure S2). We therefore decided to investigate whether
endogenous LRRTM2 contributed to synapse formation. To
determine if LRRTM2 was targeted to excitatory synapses,
hippocampal neurons were cotransfected with myc-tagged
LRRTM2 and GFP and immunostained for synaptic markers.
Myc-LRRTM2 clustered in the heads of dendritic spines, where
it colocalized with the excitatory postsynaptic marker PSD-95,
but not with the inhibitory postsynaptic marker gephyrin
(Figure 1A). The quality of immunofluorescence with currently
available LRRTM2 antibodies is not suitable to draw definitive
conclusion about the localization of the endogenous protein,
but the localization of the tagged proteins suggests that LRRTM2800 Neuron 64, 799–806, December 24, 2009 ª2009 Elsevier Inc.primarily localizes to the postsynaptic density of excitatory
synapses.
To examine the consequences of LRRTM2 loss of function,
we generated an shRNA construct against LRRTM2 to knock
down LRRTM2 expression in hippocampal neurons. The
LRRTM2 shRNA reduced expression of myc-tagged mouse
LRRTM2 in 293T cells by 90% (Figure 1B). Myc-tagged
human LRRTM2, which differs from mouse LRRTM2 by only
one nucleotide in the shRNA target sequence, was not affected
by the LRRTM2 shRNA, demonstrating target specificity
(Figure 1B). To test the efficiency of sh-LRRTM2 in knocking
down endogenous LRRTM2 protein levels in hippocampal
neurons, the H1 promoter and shRNA were cloned into a
lentiviral vector. Dissociated hippocampal neurons were
infected at DIV 6, and cell lysate was analyzed by western
blot on DIV 12. The LRRTM2 antibody (Figure S3) detects
a weak band around 90 kDa in lysates of DIV 12 hippocampal
neurons infected with the control virus, which was strongly
reduced in neurons infected with the virus encoding the
LRRTM2 shRNA (Figure 1C). Expression of sh-LRRTM2 did
Figure 2. LRRTM2Regulates GluR1 Surface
Expression in Hippocampal Neurons and
Interacts with Postsynaptic Proteins
(A) Hippocampal neurons were electroporated
with the sh-vector (sh-vec), sh-LRRTM2, and
sh-LRRTM2 with human myc-LRRTM2 (sh-
LRRTM2 + hLRRTM2), surface labeled for GluR1,
and immunostained at DIV 15 for GFP and VGlut1.
(B) Quantification of the density of synaptic
surface GluR1 puncta (VGlut1/GluR1 colocaliza-
tion) per length of dendrite normalized to sh-vec
control neurons (**p < 0.001). (C) Quantification
of the GluR1 surface puncta per length of dendrite
(**p < 0.01). (D) Quantification of the VGlut1
puncta per 10 mm dendrite. Bar graphs show
mean ± SEM (difference not significant by
ANOVA; p = 0.02 by Student’s t test for control
versus sh-LRRTM2). (E–G) 293T cells were
cotransfected with myc-LRRTM2 mutant con-
structs and GluR1-GFP (E) or GluR2-GFP (F).
Cell lysates were immunoprecipitated with myc
antibodies and were analyzed by western blot
using anti-GFP antibodies. EphB2-YFP was used
as a negative control. A representative blot
showing input samples probed with myc antibody
is shown in (G). High and low molecular weight
bands for LRRTM2 on western blot are probably
due to glycosylation of LRRTM2. (H) Coexpression
of PSD-95-mCherry with myc-LRRTM2 in 293T
cells induces translocation to the cell mem-
brane of PSD-95, which is diffusely distributed
throughout the cytosol in GFP-expressing control
cells. (I) Immunoprecipitation of myc-LRRTM2
deletion mutants lacking the cytoplasmic domain
(LRRTM2 DC) or the C-terminal ECEV motif
(LRRTM2 DECEV) coexpressed with PSD-95-
mCherry in 293T cells. LRRTM2 interacts with
PSD-95-mCherry via the ECEV motif. The high
molecular weight band is shown for LRRTM2.
Molecular weight markers in kDa indicated on
the right. Scale bar in (A) and (H), 10 mm. Error
bars represent SEM.
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samples (Figure 1C).
To determine the effects of LRRTM2 knockdown on synapse
development, we electroporated hippocampal neurons with
LRRTM2 shRNA and control constructs and immunostained the
cultures for the excitatory synapse markers PSD-95 and VGlut1
at DIV 14. Expression of sh-LRRTM2 in hippocampal neurons
resulted in a40%reduction in excitatory synapsedensity (Figures
1D and 1E), suggesting that endogenous LRRTM2 significantly
contributes to excitatory synapse development. The decrease
in excitatory synapse density following LRRTM2 knockdown
was rescued by coexpression of human myc-LRRTM2 (Figures
1D and 1E), supporting target specificity of sh-LRRTM2. Expres-
sion of sh-LRRTM2 in hippocampal neurons had no effect on
inhibitory synapse density (Figure 1F), indicating that expression
of sh-LRRTM2 does not cause a general decrease in synapse
density. These results indicate that endogenous LRRTM2
contributes to the development of excitatory, but not inhibitory,
synapses in cultured hippocampal neurons.LRRTM2 Regulates Surface Expression of GluR1-
Containing Glutamate Receptors
The LRRTM2 loss-of-function studies suggest that LRRTM2 acts
as a postsynaptic organizer of excitatory synapses in hippo-
campal neurons. A salient feature of hippocampal excitatory
synapses is the presence of postsynaptic AMPA and NMDA
receptors. To determine whether LRRTM2 recruits AMPA recep-
tors to the postsynaptic density, we analyzed GluR1 surface
expression following knockdown of LRRTM2. Neurons were
electroporated with shRNA and control constructs, surface
labeled for GluR1 at DIV 15, and subsequently permeabilized
and immunostained for GFP and VGlut1. Knockdown of
LRRTM2 resulted in a 33% decrease in the density of synaptic
GluR1 surface puncta (Figures 2A and 2B). The decrease in
density of synaptic GluR1 surface puncta following knockdown
of LRRTM2 was rescued by coexpression of human LRRTM2
(Figures 2A and 2B). The reduction in synaptic GluR1 surface
expression following LRRTM2 knockdown was caused primarily
by a decrease in the density of GluR1 surface puncta (Figure 2C),Neuron 64, 799–806, December 24, 2009 ª2009 Elsevier Inc. 801
Figure 3. LRRTM2 Is Required for Excitatory Synapse Function
In Vivo
(A) Schematic of experimental configuration. Rats were stereotaxically injected
with lentivirusatP5, andacutesliceswerecutbetweenP13andP16.Whole-cell
recordings were made from nearby infected and uninfected granule cells,
identified by DIC and GFP epifluorescence, in the granule cell layer (GCL). Per-
forant path (PP) inputs were stimulated with an electrode in the outer half of the
molecular layer (ML). (B) Overlaid GFP epifluorescence and DIC images of
a simultaneous recording. (C) LRRTM2 shRNA causes a large reduction in
AMPAR-mediated EPSCs (average AMPAR EPSC uninfected 119.5 ± 7.7 pA
[mean ± SEM]: sh-LRRTM2 50.7 ± 8.5: n = 17 pairs, p < 0.0001). For all scatter
plots, open symbols representmeans from individual experiments and the filled
symbol represents the group mean ± SEM. Inset: example average evoked PP
AMPAR EPSCs recorded simultaneously from shLRRTM2 infected (green) and
uninfected (black) GCs at a holding potential of 60 mV. (D) LRRTM2 shRNA
causes a large reduction in NMDAR-mediated EPSCs (average NMDAR
EPSC uninfected 129.0 ± 18.7 pA [mean ± SEM]: sh-LRRTM2 59.7 ± 13.5:
n = 11 pairs, p = 0.005). Inset: example average evokedPP compoundAMPAR-
and NMDAR-mediated EPSCs recorded at a holding potential of +40 mV.
Arrows indicate the time point 50 ms after the stimulus at which the NMDAR-
mediated amplitudewasmeasured. (E) LRRTM2 shRNA causes a slight reduc-
tion in AMPA/NMDA ratio (average PP AMPA/NMDA ratio uninfected
1.32± 0.21 [mean±SEM]: sh-LRRTM21.06± 0.30: n = 11 pairs, p = 0.04). Inset:
exampleaverageoverlaidAMPARandNMDAREPSCswith tracesscaled to the
peak of the AMPAREPSC. (F) LRRTM2 shRNAdoes not affect the paired-pulse
ratio (PPR) of PP inputs onto GCs (averaged PP paired-pulse ratios uninfected
1.05± 0.06 [mean±SEM]: sh-LRRTM21.01± 0.08: n = 17 pairs, p = 0.54). Inset:
example average PP EPSCs from a simultaneous recording. Stimuli were deliv-
ered at 20 Hz. Traces are scaled to the peak of the first EPSC.
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somewhat reduced (Figure 2D). This suggests that LRRTM2
acts as a postsynaptic organizer of the excitatory synapse and
recruits AMPA receptors to the postsynaptic density.
To further investigate the interaction between LRRTM2 and
glutamate receptors, we coexpressed myc-LRRTM2 together
with GFP-tagged glutamate receptor subunits in 293T cells
and examined their association by immunoprecipitation.
Remarkably, GluR1-GFP, GluR2-GFP, and NR1-GFP all copre-
cipitated with full-length LRRTM2 (Figures 2E–2G and data not
shown). Analysis of the LRRTM2 domain involved in glutamate
receptor binding showed that LRRTM2 interacts with GluR1-
GFP and GluR2-GFP via the LRR domain (Figures 2E–2G).
EphB2-YFP did not coprecipitate with LRRTM2, indicating that
coprecipitation with AMPA and NMDA receptor subunits does
not reflect nonspecific interactions with transmembrane
proteins. These data indicate that LRRTM2 can bind to gluta-
mate receptor subunits via its extracellular LRR domain. Deter-
mination of whether endogenous LRRTM2 associateswith gluta-
mate receptors in vivo will require the development of suitable
antibodies.
It is also possible that LRRTM2 recruits postsynaptic compo-
nents via an interaction with synaptic scaffolding proteins.
LRRTM proteins contain a highly conserved four amino acid
sequence (ECEV) at their C terminus that is reminiscent of
a PDZ-binding domain, suggesting that LRRTM2 might interact
with PSD-95, an abundant PDZ-domain containing scaffolding
protein (Sheng and Hoogenraad, 2007). Furthermore, several
proteomic analyses of purified postsynaptic density fractions
or immunopurified PSD-95 complexes have identified LRRTM1,
LRRTM2, and LRRTM4 as constituents of the postsynaptic
density (Dosemeci et al., 2007; Jordan et al., 2004; Yoshimura
et al., 2004). To test whether LRRTM2 can interact with PSD-
95, myc-tagged LRRTM2 was coexpressed with PSD-95-
mCherry in 293T cells. In control cells expressing GFP, PSD-
95-mCherry was distributed throughout the cytosol (Figure 2H).
Upon coexpression of myc-LRRTM2, PSD-95-mCherry translo-
cated to the cell membrane, where it colocalized with LRRTM2,
indicating that LRRTM2 can recruit PSD-95 to the cell membrane
(Figure 2H). To identify the domain of LRRTM2 that mediates
binding to PSD-95, we generated LRRTM2 deletion constructs
lacking the entire cytoplasmic domain (LRRTM2 DC) or the C-
terminal four amino acids (LRRTM2 DECEV). Both LRRTM2
mutants were no longer able to bind PSD-95 in 293T cells
(Figure 2I), indicating that the C-terminal ECEV motif in LRRTM2
mediates binding to PSD-95.
Loss of LRRTM2Function In Vivo Leads to a Reduction in
Glutamatergic Synaptic Transmission
To examine the role of LRRTM2 in synaptic function in vivo, we
generated and stereotaxically injected lentiviruses expressing
sh-LRRTM2 and GFP or a control vector into the dentate gyrus
of P5–P6 rat pups. Hippocampal slices were cut between P13
and P16, and simultaneous recordings were made from unin-
fected and nearby infected dentate granule cells. A stimulating
electrode placed in the outer half of the molecular layer was
used to stimulate perforant path (PP) inputs onto granule cells
(Figures 3A and 3B). No differences in cellular measures of integ-802 Neuron 64, 799–806, December 24, 2009 ª2009 Elsevier Inc.rity such as input resistance were found between treatment
conditions (data not shown). Simultaneous recordings showed
that knockdown of LRRTM2 in granule cells revealed a 58%
Neuron
LRRTM2 Regulation of Excitatory Synapsesreduction in the strength of AMPAR-mediated EPSCs compared
to neighboring uninfected cells (Figure 3C). In addition to
AMPAR-mediated EPSCs, the strength of NMDAR-mediated
PP inputs onto sh-LRRTM2-expressing granule cells was also
significantly reduced by 54% (Figure 3D), indicating that endog-
enous LRRTM2 contributes significantly to excitatory synaptic
transmission in vivo. LRRTM2 knockdown caused a small
reduction in the ratio of AMPAR-mediated synaptic current to
that carried by NMDARs (Figure 3E). LRRTM2 knockdown did
not affect paired-pulse ratios (PPRs), a measure of presynaptic
release probability, of the same inputs (Figure 3F). Infection
with a control virus did not affect synaptic function by any of
thesemeasures (Figure S4). Together, these results demonstrate
that loss of LRRTM2 function in vivo leads to a reduction in the
glutamatergic transmission.
The reduction in evoked EPSCs in granule cells expressing
sh-LRRTM2 could indicate a reduced number of synapses
onto granule cells or a reduced glutamate receptor density at
these synapses. To gain more insight in the consequences of
loss of LRRTM2 in vivo, we recorded spontaneous AMPAR-
mediated miniature excitatory postsynaptic currents (mEPSCs)
from lentivirus-infected granule cells. Whole-cell recordings
were made from infected cells, identified by GFP fluorescence,
and AMPA mEPSCs were isolated pharmacologically. Analysis
of AMPAR-mediated mEPSCs showed that loss of LRRTM2
in granule cells caused a small but significant decrease in
mEPSC amplitude compared to control infected neurons
(Figures S5A and S5B). The mEPSC frequency was not signifi-
cantly affected in sh-LRRTM2-infected cells (Figure S5C). The
decrease in mEPSC amplitude in sh-LRRTM2-infected granule
cells indicates a reduction in strength of individual synapses
and suggests that loss of LRRTM2 in hippocampal granule
neurons reduces the density of postsynaptic AMPA receptors.
The reduction in mEPSC amplitude, however, does not seem
to be sufficient to account for the 50% decrease in evoked
synaptic currents (Figure 3), suggesting that LRRTM2 regulates
both the efficacy of individual synapses and the number of
synaptic inputs.
The Extracellular Domain of LRRTM2 Is Required for Its
Synaptogenic Effect
To identify the domains of LRRTM2 that mediate its synapto-
genic activity, we carried out gain-of-function experiments
with full-length LRRTM2 and mutants that lack various
domains. Overexpression of LRRTM2 in hippocampal cultures
significantly increased the density of VGlut1/PSD-95-positive
puncta along dendrites of transfected neurons compared to
control neurons expressing GFP alone, indicating that LRRTM2
expression was sufficient to induce excitatory synapses
(Figures S6A and S6B). In contrast, overexpression of LRRTM2
had no effect on the density of inhibitory synapses (Figures S6C
and S6D).
To determine the relative contribution of the extra- and intra-
cellular domains of LRRTM2 to excitatory synapse formation,
hippocampal neurons were transfected with LRRTM2 deletion
constructs lacking the intra- (LRRTM2 DC) or extracellular LRR
(LRRTM2 DLRR) domains and immunostained for VGlut1 and
PSD-95. Surface expression for all deletion mutant constructswas verified in 293T cells (data not shown). Overexpression of
LRRTM2 DC resulted in a similar increase in excitatory synapse
density as overexpression of full-length LRRTM2, but overex-
pression of theDLRRmutant abolished LRRTM2’s synaptogenic
effect (Figures 4A, S6E, and S6F). This indicates that the LRR
domain is required for the LRRTM2-mediated increase in
excitatory synapse density. Neutravidin beads coated with
LRRTM2-ecto-Fc induced clustering of VGlut1 puncta in con-
tacting neurites, indicating that the ectodomain is sufficient to
induce presynaptic differentiation (Figure S6G). To determine
whether the binding partner for LRRTM2 was localized to
excitatory synapses, we incubated hippocampal cultures with
clustered LRRTM2-ecto-Fc or control Fc, and examined the
localization of LRRTM2 binding sites by costaining with anti-
VGlut1 antibodies. LRRTM2-ecto-Fc and VGlut1 puncta were
colocalized, suggesting that the LRRTM2 receptor is a synapti-
cally localized protein (Figure S6H).
Neurexin1 Is a Functional LRRTM2 Receptor
The receptors for LRRTM proteins are not known. To identify the
receptor for LRRTM2, we coupled LRRTM2-ecto-Fc or control
Fc protein to proteinA beads, and column purified synapto-
somal membrane proteins from P18 rat brains that bound
Fc-LRRTM2. LRRTM2-associated proteins were then analyzed
by MudPit tandem mass spectrometry (Washburn et al.,
2001). We repeatedly found 300 proteins to copurify with the
ecto domain of LRRTM2 while fewer than 100 proteins copuri-
fied with Fc alone. Judging by the number of peptides and
spectra hits, Neurexin family members were the most abundant
proteins identified as potentially binding Fc-LRRTM2 (Fig-
ure 4B). We performed our screen with low (150 mM) and high
(500 mM) salt washes, and under both conditions we found
no Neurexin peptides in the Fc negative control, indicating
a high level specificity in our assay (Table S1). Since many of
the peptides are common to different Neurexin proteins, these
results alone do not identify a unique Neurexin protein as the
major binding partner, but strongly suggest that a Neurexin
isoform is an LRRTM2 receptor.
To determine whether LRRTM2 binds to specific Neurexin
family proteins, we performed a series of experiments to
examine the binding of Fc-LRRTM2 to the surface of 293T cells
expressing different Neurexin isoforms (Figures 4C–4F). 293T
cells were transfectedwith the indicated isoforms, and 24 hr later
the cells were exposed to clustered LRRTM2-ecto-Fc or control
Fc proteins. Relative expression of Neurexin constructs is shown
in Figure 4E. Following a 1 hr incubation, cultures were fixed and
Fc binding assessed by immunofluorescence. As shown in
Figures 4D and 4F, there was no significant LRRTM2 binding
to control transfected cells (GFP, N-cadherin, NGL2). There
was statistically significant binding to Neurexin 1a, but not
Neurexin 2a or 3a. The highest level of binding was seen with
Neurexin 1b (Figures 4D and 4F).
Neurexin 1b contains only one extracellular LNS domain that
has previously been implicated in its interaction with Neuroligin.
To determine whether the LNS domain of Neurexin 1b was
specifically required for binding to LRRTM2, we tested two addi-
tional constructs in which the LNS domain of Neurexin 1b was
replaced by the corresponding domain from Neurexin 2 orNeuron 64, 799–806, December 24, 2009 ª2009 Elsevier Inc. 803
Figure 4. Neurexins Are Functional LRRTM2 Receptors
(A) LRRTM2 FL and LRRTM2 DC expressed in hippocampal neurons significantly increase excitatory synapse density (normalized excitatory synapse density)
(***p < 0.001; DLRR not significantly different from controls by ANOVA, but p = 0.01 for pairwise comparison with control by Student’s t test). See Figure S6E for
accompanying fluorescence images. (B) Mass spec interaction screen identifies Neurexins as potential LRRTM2 receptors. The scatter plot is a graphical repre-
sentation of a representative interaction screen. Each dot represents a protein that was identified by tandem mass spectrometry. The blue dot is LRRTM2 (bait
protein), while the red dots are Neurexin family members. Gray dots represent other proteins that were also identified. The x axis represents the number of
peptides and the y axis is the number of spectra in which the identified protein was found. (C) Schematic representation of Neurexin constructs. Neurexins
(Nrxn) 1a, 2a, 3a, and 1b refer to the wild-type proteins. Nrxn 2a1b and Nrxn 3a1b are chimeric proteins of Nrxn1b with the LNS6 domain replaced with that
of 2a and 3a, respectively. LNS, laminin, neurexin, sex-hormone-binding protein; CH, highly glycosylated region; bN, b specific leader; TM, transmembrane
domain. All constructs have a C-terminal CFP tag. (D) Relative binding of LRRTM2-ecto-Fc to 293T cells expressing either Neurexins or control constructs.
LRRTM2-Fc binds preferentially to 293T cells expressing Nrxn 1a, 1b, and 2a1b (*p < 0.05, **p < 0.005). All samples were normalized to an Fc-only control.
(E) Relative expression of Neurexin-CFP constructs expressed in 293T cells, detected on western blot with anti-GFP antibody. (F) Confocal images of
LRRTM2-ecto-Fc binding (red) to 293T cells (blue) expressing either Neurexin-CFP or control constructs. The CFP tag on neurexin constructs is pseudocolored
blue to facilitate visualization of binding. Scale bar, 20 mm. (G) Binding of LRRTM2-ecto-Fc to Neurexin 1a-expressing 293T cells as a function of LRRTM2
concentration. (H) Binding of LRRTM2-ecto-Fc to Neurexin 1b-expressing 293T cells as a function of LRRTM2 concentration. (I and J) Direct binding of
purified Neurexin 1a and 1b to immobilized LRRTM2-ecto-Fc. SDS-PAGE stained with Coomassie blue was used to separate the purified recombinant
LRRTM2-ecto-Fc and either Neurexin 1a or 1b. Molecular weight standards, in kDa, are on the left. Proteins bands are identified on the right. FT, flow through
of either Neurexin 1a (I) or Neurexin 1b (J). W1 throughW4, washes; E1 through E3, elutions. Lack of binding to Fc control protein (E1–E3) is shown at bottom. Bait
Neuron
LRRTM2 Regulation of Excitatory Synapses
804 Neuron 64, 799–806, December 24, 2009 ª2009 Elsevier Inc.
Neuron
LRRTM2 Regulation of Excitatory SynapsesNeurexin 3. The Neurexin 2a1b construct showed significant but
highly reduced binding compared to Neurexin1b, whereas the
Neurexin 3a1b construct showed no specific binding (Figures
4D and 4F). Consistent with a ligand-receptor relationship, Neu-
rexins and LRRTM2 appear not to interact in cis, as they did not
coprecipitate when coexpressed in 293T cells (data not shown).
These results indicate that Neurexin 1a and Neurexin 1b are
LRRTM2 receptors and that the LNS domain of Neurexin 1b is
critical for its ability to bind LRRTM2.
To estimate the binding affinity of LRRTM2 to Neurexin 1a and
1b, we examined relative binding of LRRTM2 at various concen-
trations to 293T cells expressing Neurexin constructs. Scatchard
plot analysis indicates LRRTM2 binding affinities as 16 nM for
Neurexin 1a and 7 nM for Neurexin 1b (Figures 4G and 4H). It
should be noted, however, that these represent affinities of
LRRTM2 for Neurexin 1a and 1b expressed on the cell surface;
an accurate intermolecular binding affinity would require analysis
with recombinant purified proteins. To determine whether
LRRTM2 directly binds to Neurexin 1a and 1b, we carried out
a direct binding assay using recombinant LRRTM2 and Neurexin
proteins. As shown in Figures 4I and 4J, both Neurexin 1a and 1b
bound to LRRTM2-ecto-Fc immobilized on protein A beads and
could be eluted from the column (lanes E2 and E3), indicating
a direct interaction between these proteins.
Finally, to address whether Neurexin1 function was needed for
LRRTM2-induced synaptic differentiation, we used the synapse
induction assay in which 293T cells expressing LRRTM2 can
induce presynaptic differentiation in cocultured hippocampal
neurons (Figure S2). Hippocampal neurons were electroporated
with either GFP or GFP together with an shRNA directed
against Neurexin 1. At DIV 5, 293T cells expressing GFP alone
or GFP + myc-LRRTM2 were overlayed on the neuronal culture.
These cocultures were fixed and immunostained for GFP to
visualize transfected axon/293T overlap and synapsin to identify
presynaptic terminals, and the number of synaptic puncta per
10 mmof axon/293T overlap was quantified. As shown in Figures
4K and 4L, LRRTM2 induced presynaptic differentiation in
control hippocampal axons. However, this effect was abolished
in hippocampal neurons expressing shNrxn1, indicating that
Neurexin1 function is necessary for LRRTM2-induced presyn-
aptic differentiation.
DISCUSSION
The observations reported here identify LRRTM2 as a key regu-
lator of excitatory synapse formation. LRRTM2 localizes to the
postsynaptic density of excitatory synapses and induces func-
tional presynaptic differentiation in contacting axons in coculture
assays. A role for LRRTM2 in regulating postsynaptic differenti-
ation is supported by the fact that LRRTM2 binds PSD-95 and
regulates AMPA receptor surface expression, and knockdownprotein is LRRTM2-ecto-Fc. (K) Hippocampal neurons transfected with GFP (left)
LRRTM2. Cocultures were immunostained for GFP to identify axon/293T overlap
of transfected axons. Note presence of synapsin puncta in control transfected ax
tification of the experiment described in (K), showing that expression of shNrxn1
Inset shows knockdown on Neurexin 1b, but not b-actin, in 293T cell lysates cotra
by LRRTM2-Neurexin1 interaction. Error bars represent SEM.of LRRTM2 in vivo decreases the strength of glutamatergic
synaptic transmission without affecting presynaptic properties.
Overexpression of LRRTM2 in cultured hippocampal neurons
increases the density of excitatory synapses, without affecting
inhibitory synapse density and knockdown of LRRTM2 in
cultured neurons selectively decreases excitatory synapse
density. Finally, we find that Neurexin1 acts as a functional
receptor for LRRTM2. Neurexin 1a and 1b both show isoform-
specific binding to LRRTM2, and knockdown of Neurexin1
blocks the ability of LRRTM2 to induce presynaptic differentia-
tion. Together, these observations indicate that LRRTM2-
Neurexin1 interactions play a critical role in the formation of
excitatory synapses (Figure 4M).
Our observations suggest that LRRTM2 regulates postsyn-
aptic function by interacting with key postsynaptic components.
LRRTM2 interacts with PSD-95, and knockdown of LRRTM2 in
dissociated neurons leads to a reduction in the density of PSD-
95 puncta. Our data suggest that LRRTM2 can recruit PSD-95
to the postsynaptic density by binding to PSD-95 via the cyto-
plasmic ECEV motif in LRRTM2. The interaction of LRRTM2
with PSD-95 is significant, as PSD-95 plays an important role
in regulating synaptic strength and plasticity by interacting with
glutamate receptors and other synaptic signaling proteins (Kim
and Sheng, 2004; Sheng and Hoogenraad, 2007; Han and
Kim, 2008).
In further support of a postsynaptic role for LRRTM2, knock-
down of LRRTM2 expression in cultured neurons strongly
reduced synaptic GluR1 surface expression. This suggests
that LRRTM2 recruits AMPARs to the postsynaptic density.
One possibility is that LRRTM2 recruits AMPARs indirectly,
through PSD-95 and TARPs (Chen et al., 2000; Schnell et al.,
2002; Be´ı¨que et al., 2006; Elias et al., 2006). Alternatively,
LRRTM2 could directly recruit AMPARs and NMDARs. We find
that LRRTM2 can interact with AMPA and NMDA receptor
subunits in heterologous cells via its extracellular domain, which
suggests that one mechanism by which LRRTM2 promotes
excitatory, but not inhibitory, synapse development could be
through direct coupling with glutamate receptors in the postsyn-
aptic membrane. This is an interesting possibility, but the inter-
actions need to be confirmed for endogenous proteins.
In addition to regulating postsynaptic function, LRRTM2 is
able to induce presynaptic differentiation. Our search for the
presynaptic LRRTM2 receptor led to the identification of
Neurexin 1a and 1b as LRRTM2 receptors. This is striking, as
these Neurexins have previously been identified as the major
receptors for Neuroligin1 (Dean et al., 2003; Ichtchenko et al.,
1995), and Neuroligin1 has been widely studied as a regulator
of excitatory synapse formation (reviewed in Craig and Kang,
2007; Su¨dhof, 2008). Thus, it appears that neurexins function
as receptors for two major classes of synaptogenic proteins.
Finally, recent findings suggest that mutations in LRRTMs,or GFP + shNRXN1 (right), cocultured with 293T cells expressing GFP + myc-
and synapsin to identify presynaptic terminals. Arrowheads mark the trajectory
ons (yellow) but not in shNrxn1-expressing axons. Scale bar, 10 mm. (L) Quan-
blocks the ability of LRRTM2 to induce presynaptic differentiation (*p < 0.05).
nsfected with shNrxn1. (M) Model of regulation of excitatory synapse formation
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LRRTM2 Regulation of Excitatory Synapsesneuroligins, and neurexins are associated with autism and other
neurological and psychiatric disorders (Majercak et al., 2006;
Francks et al., 2007; Edwards et al., 2009; Su¨dhof, 2008; Ether-
ton et al., 2009). The identification of an LRRTM-Neurexin inter-
action as a key regulator of excitatory synapses should provide
important insight into the molecular understanding of develop-
mental cognitive disorders.
EXPERIMENTAL PROCEDURES
Please see Supplemental Data for details of experimental procedures.
SUPPLEMENTAL DATA
Supplemental Data include figures, a table, and Experimental Procedures
and can be found with this article online at http://www.cell.com/neuron/
supplemental/S0896-6273(09)01009-5.
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